AstraZeneca: Gout trials

The registry lists 27 Gout studies with AstraZeneca as lead sponsor. 0 are open to participants now and 14 have results posted.

Phase 1 10Phase 2 7Phase 3 7Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UACompletedNCT03316131Phase 2Results posted
• Phase 2a RDEA3170 and Allopurinol Combination Study in Gout SubjectsCompletedNCT02498652Phase 2Results posted
• RDEA3170 Bioavailability StudyCompletedNCT02336594Phase 1Results posted
• RDEA3170 and Allopurinol Combination Study in Gout SubjectsCompletedNCT02279641Phase 1Results posted
• RDEA3170 and Febuxostat Combination Study in Gout SubjectsCompletedNCT02246673Phase 2Results posted
• Mild, Moderate and Severe Renal Impairment StudyCompletedNCT02219516Phase 1Results posted
• Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic HyperuricemiaCompletedNCT02078219Phase 2Results posted
• Lesinurad and Febuxostat Combination Extension Study in GoutCompletedNCT01808144Phase 3Results posted
• Open-Label Lesinurad Monotherapy Extension Study in GoutCompletedNCT01650246Phase 3Results posted
• Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and FebuxostatCompletedNCT01510769Phase 3Results posted
• Combining Lesinurad With Allopurinol in Inadequate RespondersCompletedNCT01510158Phase 3Results posted
• Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase InhibitorsCompletedNCT01508702Phase 3Results posted
• Combining Lesinurad With Allopurinol in Inadequate RespondersCompletedNCT01493531Phase 3Results posted
• Allopurinol Outcome StudyCompletedNCT01391325Phase 4Results posted
• Post-Authorisation Safety Study of LesinuradWithdrawnNCT04072471
• Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.CompletedNCT03272425Phase 1
• RDEA3170 PK/PD StudyCompletedNCT02608710Phase 1
• DECT Study in Allopurinol-Treated Gout PatientsCompletedNCT02393560
• A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia PatientsCompletedNCT02317861Phase 1/2
• RDEA3170 Monotherapy in Subjects With GoutCompletedNCT01927198Phase 2
• NSAID Drug Interaction StudyCompletedNCT01884272Phase 1
• Single and Multiple Dose Study in Japanese SubjectsCompletedNCT01872832Phase 1
• Lesinurad and Allopurinol Combination Extension Study in GoutCompletedNCT01808131Phase 3
• Single and Multiple Dose Study in JapaneseCompletedNCT01744379Phase 1
• Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and PrasugrelCompletedNCT01276275
• Allopurinol Combination StudyCompletedNCT01001338Phase 2
• Uric Acid Study in Healthy Male VolunteersCompletedNCT00738842Phase 1